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Abstract
Background: Maintenance of effect following treatment with galcanezumab compared to placebo in adult patients with
episodic or chronic migraine was evaluated.
Methods: In 2 similarly designed studies of patients with episodic migraine (6months) and 1 study of patients with
chronic migraine (3months), patients randomized in a 1:1:2 ratio received a subcutaneous injection of galcanezumab
120mg/month (after an initial loading dose of 240mg) or 240mg/month or placebo. Maintenance of effect during the
double-blind phase was evaluated based on a comparison of the percentages of galcanezumab- and placebo-treated
patients with maintenance of 30, 50, 75, and 100% response (defined as ≥30, ≥50, ≥75, and 100% reduction from
baseline in monthly migraine headache days [MHD]) at an individual patient level. Logistic regression analyses were
used for between treatment comparisons.
Results: A total of 1773 adult patients with episodic migraine (n= 444 for galcanezumab 120mg; n= 435 for galcanezumab
240mg; n= 894 for placebo for 2 studies pooled) and 1113 patients with chronic migraine (n= 278 for galcanezumab 120
mg; n= 277 for galcanezumab 240mg; n= 558 for placebo) were evaluated. In patients with episodic migraine, ≥50%
response was maintained in 41.5 and 41.1% of galcanezumab-treated patients (120mg and 240mg, respectively) for ≥3
consecutive months (until patient’s endpoint) and 19.0 and 20.5%, respectively, for 6 consecutive months and was significantly
greater than the 21.4 and 8.0% of placebo-treated patients at ≥3 and 6months consecutively (P< 0.001). Approximately 6% of
galcanezumab-treated patients maintained ≥75% response all 6months versus 2% of placebo-treated patients. Few
galcanezumab-treated patients maintained 100% response. In patients with chronic migraine, 29% of galcanezumab-treated
patients maintained ≥30% response all 3months compared to 16% of placebo patients while ≥50% response was
maintained in 16.8 and 14.6% of galcanezumab-treated patients (120mg and 240mg) and was greater than placebo (6.3%;
p< 0.001). Few patients maintained ≥75% response.
Conclusions: Treatment with galcanezumab 120mg or 240mg demonstrated statistically significant and clinically
meaningful persistence of effect in patients with episodic migraine (≥3 and 6 consecutive months) and in patients with
chronic migraine (for 3months).
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Background
Galcanezumab is a humanized monoclonal antibody, indi-
cated for the prevention of migraine, that binds to calci-
tonin gene-related peptide (CGRP) and prevents its
biological activity without blocking the CGRP receptor [1].
The efficacy of galcanezumab was examined in 3 random-
ized, double-blind, placebo-controlled, Phase 3 studies of
galcanezumab (120 and 240mg/month) in patients with
episodic (EVOLVE-1 and EVOLVE-2 6-month studies) or
chronic (REGAIN 3-month study) migraine [2–4]. The
mean monthly percentages of galcanezumab-treated
patients with episodic migraine or chronic migraine that
achieved ≥50% reduction in MHD was greater than the per-
centages of placebo-treated patients (60% versus 36% to 39%
and 27% versus 15%, respectively) [2–4]. For patients with
episodic migraine, galcanezumab-treated patients experi-
enced approximately 4 fewer MHD/month (versus 2 with
placebo) and patients with chronic migraine had approxi-
mately 5 fewer MHD/month (versus 3 with placebo) with a
similar effect in both galcanezumab dose groups [2–4].
Data on current treatments for migraine prevention
support that patients on recently approved and older
treatments for migraine prevention do achieve a ≥ 50%
level of response [5–7]. However, the important question
of whether a ≥ 50% reduction in monthly MHD is main-
tained over time has not been sufficiently addressed for
both episodic and chronic migraine [5, 8–10]. Further,
can the additional responses of ≥30, ≥75, and 100%
reduction in monthly MHD, also recognized to be clinic-
ally meaningful, be maintained [11–13]? For patients on
a preventive treatment, this is a particularly important
aspect since patients seek a medication with a consistent
efficacy profile over time. Clinically, tachyphylaxis has
been reported frequently by patients and physicians.
The current study evaluated data from the placebo-
controlled EVOLVE-1 and EVOLVE-2 episodic
migraine trials and the REGAIN chronic migraine
trial and compared galcanezumab treatment to pla-
cebo in the maintenance of ≥30% (chronic only), ≥50,
≥75, and 100% (episodic only) response in the reduc-
tion of MHD from baseline.
Methods
Study design
Detailed descriptions of the study design for the 2
episodic migraine (6-month) and 1 chronic migraine
(3-month) double-blind studies, have been reported separ-
ately (ClinicalTrials.gov NCT02614183, NCT02614196,
and NCT02614261) [2–4]. Briefly, adult patients were ran-
domized 1:1:2 and received subcutaneous injections of
galcanezumab 120mg/month (after a 240mg initial load-
ing dose) or 240mg/month or placebo. Episodic migraine
was defined as having between 4 and 14 MHD and at least
2 migraine attacks per month [2, 3, 14]. Chronic migraine
was defined as having headache ≥15 days per month for
≥3months and having features of migraine headache ≥8
days per month [4, 14]. The continuation or start of any
additional migraine preventive treatments was not permit-
ted; the exception for patients with chronic migraine was
the use of topiramate or propranolol provided they
entered trial on a stable dose. The ≥50, ≥75, and ≥ 100%
response rates during the 6-month (episodic) or 3-month
(chronic) study periods were key secondary objectives
(adjusted for multiple testing) and response rates at each
month (episodic and chronic studies) were secondary
outcomes (not adjusted for multiple testing). The study
protocols were reviewed and approved by the appropriate
institutional review board for each of the study sites. The
studies were conducted according to Good Clinical Practice
and the Declaration of Helsinki guidelines. Patients pro-
vided written informed consent before undergoing study
procedures. The trials are registered with ClinicalTrials.gov
(NCT02614183, NCT02614196, and NCT02614261).
Statistical method
Data from the 2 episodic migraine trials combined and 1
chronic migraine trial were included in the analysis. In
these trials, a 30, 50, 75, and 100% response rate at each
month was defined as the percentage of patients meeting
a defined threshold (≥30, ≥50, ≥75, and 100%) in the
reduction of the number of monthly MHD during the
double-blind treatment period. Only patients with both
a baseline and ≥ 1 month of non-missing post-baseline
MHD values were included in the analysis. The evalu-
ation of maintenance of effect during the double-blind
treatment period was a comparison of the percentages
of galcanezumab- and placebo-treated patients with
maintenance of ≥30, ≥50, ≥75, and 100% response at the
individual patient level. In the episodic studies, mainten-
ance of response was calculated for those with at least 3
months (until patient’s endpoint) and 6 consecutive
months and 3 consecutive months for chronic migraine. A
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logistic regression analysis was used for between-treatment
group comparisons. At each month, a cumulative 50%
maintenance of response was also calculated and defined as
patients with ≥50% response at a specific month (or before)
and all subsequent months. For repeated binary data of
monthly ≥50% response and cumulative ≥50% sustained
response, a categorical, pseudolikelihood-based repeated
measures model was implemented with SAS PROC GLIM-
MIX [15]. Two-sided p-values were calculated and com-
pared with significance level of 0.05.
Results
Patient disposition
Data from the episodic migraine trials were from
1773 adult patients with episodic migraine treated
with 120 mg galcanezumab (n = 444), 240 mg galcane-
zumab (n = 435), or placebo (n = 894). Data from the
chronic migraine trial were from 1113 patients with
chronic migraine treated with 120 mg galcanezumab
(n = 278), 240 mg galcanezumab (n = 277), or placebo
(n = 558). Baseline demographics and disease charac-
teristics of the episodic and chronic migraine populations
show that over 80% were female, over 74% were white,
had a mean age of 40 years, and had migraine disease dur-
ation of 20 years. As permitted by protocol for the chronic
migraine trial, concomitant use of topiramate or propran-
olol during the double-blind phase, across all treatment
groups, occurred in 10.3 and 3.6% of patients, respectively.
At baseline, the mean MHD/month was 9.1 for episodic
migraine and 19.3 for chronic migraine. The mean base-
line Migraine Disability Assessment score for patients
treated with galcanezumab or placebo was 33.1 for
episodic migraine and 65.8 (galcanezumab) and 68.7
(placebo) for chronic migraine and was reflective of severe
(episodic) and very severe (chronic) migraine disability.
The mean baseline Migraine-Specific Quality of Life
Questionnaire Role Function-Restrictive subdomain score
for patients treated with galcanezumab or placebo with
episodic migraine was 51.1 and 52.1, respectively, and with
chronic migraine was 39.1 and 38.4, respectively. Patients
with chronic migraine had greater functional impairment
than patients with episodic migraine (Table 1).
Proportions of patients with ≥50% response
The model-estimated proportions of patients with
episodic migraine achieving ≥50% response were signifi-
cantly greater for both galcanezumab dose groups com-
pared to placebo starting at Month 1 (p < 0.001) and at
each month after (p < 0.001), as well as overall across 6
months (p < 0.001) (Table 2). For patients with chronic
migraine, the model-estimated proportions of patients
achieving ≥50% response was significantly greater for
both dose groups compared to placebo starting at
Month 1 (p < 0.001) and at each month after (p ≤ 0.004),
as well as overall across 3 months (p < 0.001) (Table 2).
The absolute values for the proportions of patients with
episodic or chronic migraine that achieved ≥50%
response were very similar to the estimated values pro-
portions and are shown in Additional file 1: Table S1.
Maintenance of response
Significantly more patients with episodic migraine
treated with galcanezumab in both dose groups
(approximately 41%) maintained response of ≥50%
fewer MHD for ≥3 consecutive months until patient’s
endpoint compared to placebo (21%). Over Month 1
to Month 6, approximately 20% of galcanezumab-
treated patients in both dose groups maintained a
response of ≥50% fewer MHD that was significantly
greater than placebo (8%) (Fig. 1).
In patients with chronic migraine, significantly more
patients in both the 120 mg (17%) and 240 mg (15%)
galcanezumab dose groups maintained a response of
≥50% fewer MHD for 3 consecutive months com-
pared to placebo (6%) (Fig. 2). The difference between
dose groups for either episodic or chronic migraine in
the proportions of patients with maintenance of
response was not significant.
The model-estimated proportions of patients with
episodic migraine who maintained a response of ≥75
and 100% and those patients with chronic migraine
who maintained a response of ≥30 and ≥ 75% are
shown in (Table 3). The proportions of galcanezumab-
treated patients with episodic migraine who maintained
a response of ≥75% fewer MHD for 3 consecutive
months until patient’s endpoint (19.7 and 21.3%) was
significantly greater than placebo (8.5%; p < 0.001).
While fewer, 6% of galcanezumab-treated patients
maintained a response of ≥75% fewer MHD for all 6
months compared with 1.8% of placebo-treated
patients. A small percentage of patients maintained
100% response for 3 consecutive months and very few
maintained 100% response for all 6 months. The pro-
portions of galcanezumab-treated patients with chronic
migraine who maintained a response of ≥30% fewer
MHD for all 3 months (29%) was significantly greater
than placebo (16.4%; p < 0.001). The proportions of
patients who maintained ≥75% fewer MHD for all 3
months was not different between the galcanezumab
and placebo groups.
Characterization of patients with episodic migraine with
≥50% response at month 1
Among the 50.9 and 47.2% of galcanezumab 120mg- and
240mg-treated patients with episodic migraine who met
≥50% response at Month 1, the average reduction in MHD
over the remaining 5months of the double-blind phase was
66.6 and 71.5%. Of the 23.8% of placebo-treated patients
Förderreuther et al. The Journal of Headache and Pain          (2018) 19:121 Page 3 of 9
with ≥50% response at Month 1, the average reduction in
MHD was 63.2%. Further, among only those with ≥50%
response at Month 1, 85.4 and 92.4% of patients in the 2
galcanezumab dose groups and 80.7% in the placebo group
averaged at least a 40% response over the remaining 5
months. Moreover, 80.8 and 85.4% of patients in the 2 gal-
canezumab groups respectively and 71.1% of patients in the
placebo group averaged at least ≥50% response over the
remaining 5months.
Cumulative and onset of maintenance of response
The cumulative maintenance of response is defined as
individual patients who met ≥50% response starting at a
given month (or before) and then all the months subse-
quent. The proportions of patients with episodic
migraine in the galcanezumab 120 mg and 240mg
groups achieving cumulative maintenance of ≥50%
response was superior to placebo at every month of the
6-month double-blind phase (p < 0.001) (Fig. 3). For
example, 31% of patients with episodic migraine treated
with galcanezumab 120 mg reached ≥50% at or before
Month 3 and maintained that response in the subse-
quent months (Month 4 to Month 6). The difference
between the galcanezumab dose groups for cumulative
maintenance of response was not significant.
The onset of ≥50% maintenance of response and
the percentage of patients with episodic or chronic
migraine who reached ≥50% response at the specific
month (but not before) and then maintained that
response in the subsequent months of treatment is
shown in Table 4. To illustrate the onset for patients
with episodic migraine, 19, 6, and 6% of patients
treated with galcanezumab 120 mg reached ≥50% re-
sponse at Months 1, 2, and 3, respectively, and main-
tained that response in the subsequent months of
treatment (Months 2 to 6, Months 3 to 6, and Month
4 to 6, respectively). Across the 6-month double-blind
phase, onset of maintenance of response occurred for
approximately 4 to 21% of galcanezumab-treated pa-
tients with highest rate occurring in Month 1. In all
but one time point, the proportions of patients were
greater in the galcanezumab treatment groups than
the placebo group at each month. The exception was
at 6 months where the proportions of patients were
similar between the galcanezumab 120 mg (10.6%)
and placebo (10.9%) groups.
Table 1 Patient demographics and disease characteristics of galcanezumab -treated patients from episodic and chronic migraine trials
Variables Episodic Migraine Studiesa Chronic Migraine Studyb
Galanezumaba
N = 879
Placebo
N = 894
Galcanezumabb
N = 555
Placebo
N = 558
Age, years, mean (SD) 40.7 (11.4) 41.9 (11.4) 40.4 (12.2) 41.6 (12.1)
Female, n (%) 744 (84.6) 755 (84.5) 463 (83.4) 483 (86.6)
Race white, n (%) 652 (74.2) 681 (76.2) 447 (80.7) 432 (77.4)
Ethnicity not Hispanic or Latinoc, n (%) 664 (78.4) 677 (79.4) 387 (74.0) 401 (76.7)
Geographic region, n (%)
North America 647 (73.6) 657 (73.5) 320 (57.7) 321 (57.5)
Europe 119 (13.5) 122 (13.7) 138 (24.9) 140 (25.1)
Other 113 (12.9) 115 (12.9) 97 (17.5) 97 (17.4)
Body mass index, kg/m2 mean (SD) 27.6 (5.5) 27.6 (5.5) 26.5 (5.4) 26.9 (5.6)
Migraine disease duration, years, mean (SD) 20.1 (12.2) 20.5 (12.5) 20.2 (12.7) 21.9 (12.9)
Migraine headache days/month, mean (SD) 9.1 (2.9) 9.1 (3.0) 19.3 (4.4) 19.6 (4.6)
MHD/month with acute medication use, mean (SD) 7.4 (3.4) 7.5 (3.4) 14.8 (6.3) 15.5 (6.6)
Headache days/month, mean (SD) 10.7 (3.7) 10.6 (3.4) 21.3 (4.0) 21.5 (4.1)
Migraine with aura, n (%) 467 (53.1) 471 (52.7) 294 (53.0) 310 (55.6)
Prior preventive treatment in past 5 years, n (%) 559 (63.6) 555 (62.1) 431 (77.7) 435 (78.0)
Failed≥ 2 preventives in past 5 years, n (%) 88 (10.0) 85 (9.5) 165 (29.7) 163 (29.2)
MIDAS total, mean (SD) 33.1 (28.2) 33.1 (29.3) 65.8 (57.3) 68.7 (57.4)
MSQ RF-R, mean (SD) 51.1 (16.1) 52.1 (15.6) 39.1 (17.3) 38.4 (17.2)
PGI-S, mean (SD) 4.3 (1.2) 4.3 (1.2) 4.8 (1.3) 4.9 (1.2)
Abbreviations: MHD migraine headache days, MIDAS Migraine Disability Assessment, MSQ Migraine-Specific Quality of Life Questionnaire version 2.1, PGI-S Patient
Global Impression of Severity, RF-R Role Function-Restrictive, SD standard deviation
aPooled data from two parallel 6-month trials in patients with episodic migraine
b3-month trial
cNot all patients reported ethnicity data
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In patients with chronic migraine, the proportions of
patients treated with galcanezumab 120 mg or 240 mg
achieving cumulative maintenance of ≥50% response
was superior to placebo at every month of the 3-month
double-blind phase (p < 0.001). At Month 3 or before,
approximately 30% of patients in the galcanezumab
treatment groups achieved and maintained ≥50%
response (Fig. 4). The difference between the galcanezu-
mab dose groups for cumulative maintenance of
response was not significant. To illustrate the onset of
the maintenance of ≥50% response for patients with
chronic migraine (Table 4), 15, 5, and 11% of patients
treated with galcanezumab 120 mg reached ≥50%
response at Month 1, 2, and 3, respectively.
Safety and tolerability
The most commonly reported treatment-emergent ad-
verse events (TEAE) were injection site-related pain,
reaction, erythema, pruritus, and swelling. Discontinu-
ation due to an injection site-related TEAE was low
(< 0.5% across all 3 trials). There were no significant
differences between galcanezumab and placebo in
changes in vital signs and blood pressure. The safety
Fig. 1 Episodic migraine: proportions of patients with maintenance of≥ 50% response for≥ 3 consecutive months until patient’s endpoint and
response from month 1 to month 6. a maintenance of≥ 50% response for ≥ 3 consecutive months. b maintenance of≥ 50% response from
month 1 to month 6. Abbreviations: OR = odds ratio. *** = p < 0.001
Table 2 Model-estimated proportion of patients with episodic and chronic migraine with ≥ 50% response
Response rate Galcanezumab 120mg
(N = 436)
Galcanezumab 240mg
(N = 428)
Placebo
(N = 875)
Episodic migraine
Overall 6 months 60.8% 58.7% 37.2%
Odds ratio (95% CI) 2.6 (2.2, 3.1)* 2.4 (2.0, 2.8)*
Month 1, % 50.9% 47.2% 23.8%
Odds ratio (95% CI) 3.3 (2.6, 4.2)* 2.9 (2.2, 3.7)*
Month 6, % 65.7% 63.2% 44.3%
Odds ratio (95% CI) 2.4 (1.9, 3.1)* 2.2 (1.7, 2.8)*
Chronic migraine Galcanezumab 120mg
(N = 273)
Galcanezumab 240mg
(N = 274)
Placebo
(N = 538)
Overall 3 months 27.6% 27.5% 15.4%
Odds ratio (95% CI) 2.1 (1.6, 2.8)* 2.1 (1.6, 2.8)*
Month 1, % 23.7% 21.2% 9.9%
Odds ratio (95% CI) 2.8 (1.9, 4.2)* 2.5 (1.7, 3.6)*
Month 3, % 31.9% 34.0% 22.4%
Odds ratio (95% CI) 1.6 (1.2, 2.3)† 1.8 (1.3, 2.5)*
Abbreviations: CI confidence interval
*p < 0.001 versus placebo
†p ≤ 0.004 versus placebo
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profile between the 120 mg and 240 mg doses were
similar [2–4].
Discussion
Treatment with galcanezumab 120 mg or 240 mg dem-
onstrated statistically significant and clinically meaning-
ful maintenance of effect in patients with episodic
migraine (≥3 consecutive months until patient’s
endpoint and 6 consecutive months) or chronic migraine
(3 months). Starting at Month 1, about 20% of
galcanezumab-treated patients (either dose group) with
episodic migraine had a sustained response of ≥50%
reduction of MHD over 6 months; about 41% of patients
maintained ≥50% response over ≥3 months. Among only
Table 3 Model-estimated proportion of patients with episodic and chronic migraine with maintained response
Response rate Galcanezumab 120mg
(N = 436)
Galcanezumab 240mg
(N = 428)
Placebo
(N = 875)
Episodic migrainea
75% Response ≥3 consecutive monthsb 19.7% 21.3% 8.5%
Odds ratio (95% CI) 2.7 (1.9, 3.7)* 2.9 (2.1, 4.1)*
75% Response all 6 months 6.2% 6.8% 1.8%
Odds ratio (95% CI) 3.5 (1.9, 6.3)* 3.9 (2.1, 6.9)*
100% Response ≥3 consecutive monthsb 3.7% 6.5% 2.7%
Odds ratio (95% CI) 1.4 (0.7, 2.5) 2.5 (1.4, 4.2)*
100% Response all 6 months 0.7% 1.4% 0.2%
Odds ratio (95% CI) 2.9 (0.8, 10.4) 5.3 (1.6, 17.1)†
Chronic migrainec Galcanezumab 120mg
(N = 273)
Galcanezumab 240mg
(N = 274)
Placebo
(N = 538)
30% Response all 3 months 29.3% 29.2% 16.4%
Odds ratio (95% CI) 2.1 (1.5, 3.0)* 2.1 (1.5, 3.1)*
75% Response all 3 months 2.6% 2.9% 2.0%
Odds ratio (95% CI) 1.3 (0.6, 3.1) 1.5 (0.6, 3.4)
Abbreviations: CI confidence interval
a6-month study
bMaintained response until patient’s endpoint of the 6-month, double-blind period
c3-month study
*p < 0.001 versus placebo
† p = 0.006 versus placebo
Fig. 2 Chronic migraine: proportions of patients with maintenance of≥ 50% response for 3 consecutive months. Abbreviations: OR = odds
ratio. *** = p < 0.001
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the galcanezumab-treated patients who had a ≥ 50%
reduction of MHD in Month 1, an average reduction of
MHD of ≥40 and ≥ 50%, was achieved by 89 and 83% of
patients, respectively, in the remaining 5months of
treatment suggesting minimal loss of efficacy among
Month 1 responders. In galcanezumab-treated patients
with chronic migraine, about 15% showed a ≥ 50% reduc-
tion of MHD over 3 consecutive months. Sustained
efficacy was also observed in the placebo groups of
patients with episodic and with chronic migraine; how-
ever, the placebo response was always significantly inferior
to galcanezumab treatment. For example, galcanezumab-
treated patients with episodic migraine were well over 2
times more likely than placebo-treated patients to achieve
a sustained ≥50% response at 6 months and overall. Simi-
larly, galcanezumab-treated patients with chronic
migraine were twice as likely than placebo-treated patients
to achieve a sustained ≥50% response at 3months and
overall. Several studies have shown the importance of
expectation for the size of the placebo response and so a
relatively high placebo response, typical for controlled
treatment studies in migraine, was not an unexpected
observation in our analysis [16–18]. The placebo response
rate is likely a result of intensive patient care within the
setting of a study. Regardless, the importance of this
analysis is based on the fact that responders do not
develop tachyphylaxis, for example, by up-regulation of
other mediators of neurovascular inflammation.
Studies with monoclonal antibodies have shown sus-
tained levels of 50% as well as 75 and 100% response in
patients with episodic or chronic migraine [10]. Based
on pre-specified analyses for our study, about 41% of
galcanezuamb-treated patients with episodic migraine
maintained ≥50% response for ≥3 consecutive months
until patient’s endpoint and is a clinically relevant find-
ing. In the additional post-hoc analysis of assessing the
cumulative and onset of maintenance of ≥50% response,
most patients reach ≥50% response and all subsequent
months starting at Month 1, with approximately similar
percentages of patients reaching ≥50% response and all
subsequent months starting at Month 2, 3, 4, 5, and 6.
These findings were generally consistent in the chronic
Table 4 Onset of 50% maintenance of response in patients with episodic and chronic migraine: percentage of patients reach 50%
response at each month and all the subsequent months
Episodic migraine Chronic migraine
Galcanezumab 120mg
(N = 436)
Galcanezumab 240mg
(N = 428)
Placebo
(N = 875)
Galcanezumab 120mg
(N = 273)
Galcanezumab 240mg
(N = 274)
Placebo
(N = 538)
Month 1 19.0% 20.8% 8.0% 14.8% 12.7% 5.6%
Month 2 6.2% 7.7% 5.0% 4.5% 6.6% 6.2%
Month 3 6.0% 4.3% 3.2% 10.9% 13.1% 9.0%
Month 4 7.8% 5.1% 4.2% N/A N/A N/A
Month 5 6.9% 8.5% 5.8% N/A N/A N/A
Month 6 10.6% 7.9% 10.9% N/A N/A N/A
Abbreviations: N/A not applicable
Fig. 3 Cumulative maintained≥ 50% response: percentages of patients with episodic migraine who reached≥ 50% response at or before each
month and all subsequent months
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migraine study although the percentages of patients with
maintenance of response were generally lower given the
higher baseline number of MHD. The 50% responder
rate has been used as a secondary end-point in other
trials, for example, with topiramate and botulinum toxin,
in episodic and chronic migraine [5, 7, 19]. Comparison
of those results to our data are difficult because only the
50% responder rate at the end of the double-blind period
or at the end of cycle with botulinum toxin without any
monthly and maintenance of response analysis was
published.
Early and sustained response to preventive treatment is
of special relevance. There is some evidence that
improvement with preventive treatment at 3months
might be a predictor of persistent remission [20]. In
addition, there is emerging evidence that more severely
affected patients with a history of medication overuse, a
high frequency of migraine attacks, and previously inef-
fective preventive treatments require long-term preventive
treatment to maintain a reduced attack frequency, even
after withdrawal of the preventive medication [21–23].
The maintenance of effect in patients with episodic
or chronic migraine were similar between the galca-
nezumab 120 mg and 240 mg dose. This finding is
consistent with previous reports in which there were
no meaningful differences in efficacy measures
between the galcanezumab doses and as such, the
recommended dose is 120 mg after an initial loading
dose of galcanezumab 240 mg (given as two 120 mg
injections) [2–4].
One of the limitations of this paper is that the re-
sponse rate was defined based on the primary efficacy
measure, reduction in the number of MHD only.
Additional analyses could be conducted in further
publications to assess the response rate based on
other efficacy measures, such as days of acute medi-
cation use, and measures of function and disability.
Conclusions
Treatment with galcanezumab 120 mg or 240 mg
demonstrated statistically significant and clinically
meaningful maintenance of effect in patients with epi-
sodic migraine (at least 3 and 6 consecutive months)
and in patients with chronic migraine (for 3 months).
Additional file
Additional file 1: Table S1. Absolute proportion of patients with
episodic and chronic migraine with ≥50% response. (DOCX 48 kb)
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